The $1.9 Billion Pill That Replaced a Needle

To understand why EKTERLY matters, you need a quick tour of what goes wrong in HAE. Think of it like a plumbing problem.

Normally, your body has a protein called C1-inhibitor that acts like a shut-off valve, keeping a cascade of enzymes in check. In HAE patients, that valve is broken (or missing entirely). Without it, an enzyme called plasma kallikrein runs wild and chops up another protein to produce bradykinin, a molecule that makes blood vessels leak fluid into surrounding tissue. That leaking is the swelling.

Existing injectable treatments tackle this problem at various points: some replace the broken valve (C1-inhibitor concentrates), some block the signal at the very end (icatibant blocks the bradykinin receptor), and one blocks plasma kallikrein directly (ecallantide, but it's a protein that has to be injected).

Sebetralstat is a small molecule that blocks plasma kallikrein orally. Two tablets, 600 mg total, taken at the first sign of an attack. Lab studies show it achieves near-complete inhibition of plasma kallikrein within about 15 minutes of dosing. No needles, no refrigeration, no healthcare professional required.

It's the difference between grabbing Advil from your bag and setting up an IV in your kitchen.

The Data That Made Chiesi Write the Check

EKTERLY's approval rested on the KONFIDENT trial: a phase 3, randomized, placebo-controlled crossover study in patients 12 and older. The headline result was striking. Patients on the 600 mg dose experienced the beginning of symptom relief in a median of 1.79 hours, compared to 6.72 hours on placebo.

That gap matters enormously when your abdomen feels like it's being crushed or your airway is compromising. The drug also showed faster reduction in attack severity and quicker full resolution compared to placebo.

Safety was equally clean. Treatment-related adverse event rates were actually lower on the drug (3.2% at 600 mg) than on placebo (4.8%). The most common side effect? Headache. No serious adverse events. No withdrawals.

The open-label extension study, KONFIDENT-S, reinforced the story. In real-world-like conditions, patients treated attacks within a median of 9 minutes after onset, and symptom relief began in roughly 1.8 hours across high-risk attack types, including the dangerous laryngeal (throat) ones.

Why Chiesi, and Why Now?

Chiesi isn't a household name in the U.S., but the privately held Italian company has been quietly building a rare disease empire. Their strategy revolves around three pillars they call "Air, Care, and Rare." The rare disease unit generated €763 million in 2024, up 41% from the prior year, representing 22% of total company revenue.

The KalVista deal follows a clear playbook. In 2023, Chiesi acquired Amryt Pharma to establish its rare disease commercial base. Since then, it has stacked partnerships in gene editing (Arbor Biotechnologies), blood-brain barrier technology (Aliada Therapeutics, Key2Brain, Bioasis), and lysosomal storage disorders. KalVista adds rare immunology to the portfolio and, crucially, brings a commercial-stage asset rather than just a pipeline bet.

The HAE market is sizable for a rare disease: estimated at roughly $3.1 to $3.6 billion in 2025. And the unmet need remains real. An oral rescue option could meaningfully change the treatment landscape.

The Competitive Chessboard

EKTERLY doesn't exist in a vacuum. Takeda dominates the current HAE landscape with lanadelumab (Takhzyro, an injectable prophylactic antibody), icatibant (Firazyr, an injectable on-demand treatment), and various C1-inhibitor products. BioCryst sells berotralstat (Orladeyo), the only oral prophylactic kallikrein inhibitor, taken daily to prevent attacks.

Notice the distinction: berotralstat prevents attacks; sebetralstat treats them once they start. Same biological target (plasma kallikrein), completely different use cases. In fact, the two drugs are natural complements. A patient could take berotralstat every day to reduce attack frequency, then pop EKTERLY when a breakthrough attack hits.

That combination story is powerful because it normalizes an all-oral treatment paradigm for HAE patients. No more refrigerators stocked with injectable kits. No more needle anxiety during a crisis.

What the Street Already Knew

Analysts weren't blindsided by the deal. Morningstar had a fair value estimate north of $61 at one point, suggesting the $27 takeout left significant standalone value on the table.

KalVista had cash to fund operations into 2026 but would have needed capital to fuel a full commercial launch. Chiesi removes financing risk, execution risk, and global distribution challenges in one stroke. For shareholders who bought at $4, $8, or even $13, this was a clean and lucrative exit.

For Chiesi, the math is straightforward: own the only oral on-demand HAE therapy in a multi-billion-dollar market with significant unmet need. That's not just a drug acquisition. That's a category-defining bet.